Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glumetinib + Osimertinib in EGFR-mutant/MET-positive NSCLC
NCT06908772Phase 3Not yet recruiting
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Apr 2025
- Primary completion
- Dec 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 3 trial of glumetinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
glumetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06908772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06908772.